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Abstract
Background
Veterans  with  type  1  diabetes  who live  in  rural  Alabama and
Georgia face barriers to receiving specialty diabetes care because
of a lack of endocrinologists in the Central  Alabama Veterans
Health Care System. Telemedicine is a promising solution to help
increase  access  to  needed  health  care.  We  evaluated
telemedicine’s effectiveness in delivering endocrinology care from
Atlanta-based endocrinologists.
Methods
We conducted a retrospective chart review of patients who were
enrolled in the Atlanta VAMC Endocrinology Telehealth Clinic
from June  2014  to  October  2016.  Outcomes  of  interest  were
hemoglobin A1c levels, changes in glycemic control, time savings
for patients, cost savings for the US Veterans Health Administra-
tion, appointment adherence rates, and patient satisfaction with
telehealth.
Results
Thirty-two patients with type 1 diabetes received telehealth care
and in general received the recommended processes of diabetes
care. Patients trended toward a decrease in mean hemoglobin A1c
and glucose variability and a nonsignificant increase in hypogly-
cemic episodes.  Patients  saved 78 minutes of  travel  time (one
way), and the VA saved $72.94 in travel reimbursements per pa-
tient visit. Patients adhered to 88% of scheduled telehealth ap-
pointments on average, and 100% of surveyed patients stated they
would recommend telehealth to other veterans.
Conclusions
Specialty diabetes care delivered via telemedicine was safe and
was associated with time savings, cost savings, high appointment
adherence rates, and high patient satisfaction. Our findings sup-
port growing evidence that telemedicine is an effective alternative
method of health care delivery.
Introduction
The diabetes epidemic is continuously growing in America and af-
fects 29.1 million Americans (9.3% of the US population) (1). The
burgeoning prevalence of diabetes has created an increase in de-
mand for specialty diabetes care. However, there is a nationwide
shortage of approximately 1,500 full-time endocrinologists (2),
creating a disparity between diabetes care and specialty diabetes
providers.
Patients who live in rural areas, approximately 20% of the US
population, have more barriers to receiving specialty care. Barri-
ers such as long travel  distances and costly expenses to urban
areas where specialty care is  often available (3,4) create chal-
lenges for these patients to achieve good health (4). Telemedicine,
the exchange of medical information via electronic communica-
tions such as clinical video telehealth (CVT) (real-time videocon-
ferencing between patients and providers), has emerged as a prom-
ising  solution  (5,6).  The  US  Veterans  Health  Administration
(VHA) created the Telehealth Services Program to increase ac-
cess to specialty medical care for veterans with limited access (7).
In 2014, the Atlanta Veterans Affairs Medical Center (VAMC)
Endocrinology Telehealth Clinic was established to deliver spe-
cialty diabetes care to patients with type 1 diabetes in the Central
Alabama Veterans Health Care System (CAVHCS); because the
CAVHCS serves rural communities in Alabama and west Georgia,
specialty diabetes care is often inaccessible for these patients.
We characterized the effectiveness of the Atlanta VAMC Endo-
crinology Telehealth Clinic in improving diabetes outcomes for
patients with type 1 diabetes and increasing their access to spe-
cialty diabetes care. We studied patients with type 1 diabetes be-
cause the Atlanta VAMC Endocrinology Telehealth Clinic was
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health
and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2018/17_0168.htm • Centers for Disease Control and Prevention      1
created to increase access to specialty care for type 1 diabetes pa-
tients who manage their condition with insulin pump therapy. We
hypothesized that management of type 1 diabetes via CVT leads to
improvements in glycemic control, saves costs for the VHA, saves
time for patients, and is associated with high appointment adher-
ence and patient satisfaction.
Methods
CAVHCS serves more than 134,000 veterans in 43 counties of
Alabama and Georgia but does not employ a local endocrinologist.
In 2014, the Atlanta VAMC Endocrinology Telehealth Clinic was
established to increase access to specialty care for type 1 diabetes
for CAVHCS patients. Without telehealth, CAVHCS patients have
to travel to the Veterans Affairs (VA) medical centers in either
Birmingham, Alabama, or Atlanta, Georgia, to receive in-person
specialty care. With telehealth, patients travel to local community-
based outpatient clinics for their telehealth appointment, where
they check in as they would for a regular face-to-face appoint-
ment; they have their vital signs checked, go to a patient care room
with a webcam or dedicated telehealth monitor, and have a CVT
consultation from an Atlanta-based endocrinologist with in-per-
son assistance from a telehealth pharmacist. Visits typically last 30
to 60 minutes.
We conducted a retrospective chart review of patients with type 1
diabetes who received care through the Atlanta VAMC Endo-
crinology Telehealth Clinic from June 2014 to October 2016. We
collected data about changes in glycemic control, telemedicine’s
capacity to save costs for the VHA and time for patients, patient
adherence to telemedicine appointments, and patient satisfaction
with telemedicine. Data were stored in REDCap, a secure web-
based database application. Our use of REDCap was sponsored by
the Atlanta Clinical and Translational Science Institute. This study
was approved by the Emory institutional review board and the At-
lanta VA Research and Development Committee.
To assess diabetes management, we collected data on recommen-
ded processes of diabetes care: blood pressure management, eye
screening, urine microalbumin-to-creatinine ratio, and lipid panels
(triglycerides, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol).  We also assessed whether patients re-
ceived drug prescriptions for which they were eligible, specific-
ally statins and aspirin.
To assess diabetes outcomes, we collected data on change in gly-
cemic control, specifically hemoglobin A1c levels, 2-week fre-
quency  and  severity  of  hypoglycemia,  2-week  frequency  and
severity of hyperglycemia, and plasma glucose variability. Hemo-
globin A1c indicates average plasma glucose concentration over 2
to 3 months and predicts diabetes complications (8,9). Hypogly-
cemia is defined as low plasma glucose concentration, and severe
hypoglycemia may lead to unconsciousness (9). We defined hy-
poglycemia as a plasma glucose level of less than 70 mg/dL and
severe hypoglycemia as less than 40 mg/dL. Hyperglycemia is
defined as high plasma glucose concentration, which may lead to
long-term complications such as diabetic retinopathy,  nephro-
pathy,  and  neuropathy  (10).  We  defined  hyperglycemia  as  a
plasma glucose level of more than 250 mg/dL and severe hyper-
glycemia as more than 300 mg/dL. We reviewed patients’ insulin
pump downloads or patients’ glucose logs over a 2-week period to
determine frequency of hypoglycemia and hyperglycemia. Lastly,
average glucose variability was defined as the standard deviation
(SD) of all plasma glucose levels in the 2-week period. Data on
glycemic control were collected at baseline visits, 6 month follow-
up visits (±1 month), and 12 month follow-up visits (±1 month).
Cost savings for the VHA were calculated on the basis of the dif-
ference between patient travel reimbursement costs associated
with in-person visits at VA medical centers in either Birmingham,
Alabama, or Atlanta, Georgia, and costs associated with telemedi-
cine visits at community-based outpatient clinics. Travel reim-
bursements were calculated using reimbursement rates published
by the VHA’s Beneficiary Travel Benefits program, which was
41.5 cents per mile with a $6 patient deductible (11). Patients who
traveled more than 75 miles one way were eligible for VA-reim-
bursed overnight lodging, and lodging costs of $75 were added to
the travel cost for an in-person visit. Time savings for patients
were calculated using Google Maps (Google Inc) and were based
on the difference in estimated time to travel to community-based
outpatient clinics versus the nearest VA medical center in either
Atlanta, Georgia, or Birmingham, Alabama.
To evaluate telemedicine appointment adherence, we recorded the
number of CVT appointments missed (patient did not show up),
cancelled, and scheduled. Telemedicine appointment adherence
was reported as the ratio of the number of CVT appointments in
which the patient showed up to the number of CVT appointments
scheduled, excluding the number of appointments cancelled by the
patient in advance. To assess patient satisfaction with telemedi-
cine, we administered via telephone a satisfaction survey pub-
lished by the VA Telehealth Services Program. Patients were sur-
veyed about telemedicine’s usability and convenience, and their
satisfaction was measured using a Likert Scale with scores ran-
ging from 1 through 5 (1 = “strongly agree” and 5 = “strongly dis-
agree”).
Data analysis was performed using Microsoft Office Excel 2010
(Microsoft Corporation), SPSS version 23.0 (IBM Corp), and SAS
version 9.4 (SAS Institute Inc). To analyze changes in diabetes
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outcomes, we conducted paired t tests from baseline data, 6-month
follow-up data, and 12-month follow-up data. Significance was set
at P < .05. To analyze patient satisfaction survey results, we calcu-
lated the median, mean, and SDs of patient responses to each sur-
vey question.
Results
Demographic characteristics
Among 54 patients enrolled in the Atlanta VAMC Endocrinology
Telehealth Clinic, 32 patients had type 1 diabetes (Figure). Of the
32 patients  with  type  1  diabetes,  17  had follow-up visits  at  6
months, and 9 had follow-up visits at 12 months. Telehealth pa-
tients with type 1 diabetes were predominately male (n = 29, 91%)
and white (n = 27, 84%) (Table 1). Mean age was 53.5 years and
mean body mass index was 27.6 kg/m2. Comorbidities and dia-
betes complications were highly prevalent at baseline in this pa-
tient population; most patients had hyperlipidemia (n = 26, 81%)
and diabetic neuropathy (n = 23, 72%).
Figure. Diagram showing criteria for inclusion in a study of patients (N = 32)
enrolled in the Atlanta VA Telehealth Endocrine Clinic, June 2014 to October
2016. Abbreviation: VAMC, Veterans Affairs Medical Center.
 
Telehealth patients generally received the standard processes of
diabetes care (Table 2) (12). At baseline, 94% patients (30 of 32)
had a diabetic retinopathy eye screening within the preceding 2
years, and 100% (9 of 9) received the recommended eye screen-
ing at 12-month follow-up. Furthermore, 81% of patients (26 of
32) had their urine microalbumin-to-creatinine ratio measured at
baseline, which increased to 89% (8 of 9) at 12-month follow-up.
Of patients who were eligible for statin use, 89% (24 of 27) were
prescribed a statin, and 64% patients who were eligible for aspirin
use (14 of 22) were prescribed aspirin. At 12-month follow-up,
88% of eligible patients (7 of 8) were prescribed a statin, and 50%
of eligible patients (1 of 2) were prescribed aspirin. When seen at
baseline visits and at 6-month and 12-month follow-up visits, all
patients had received the recommended blood pressure measure-
ments and lipid panels.
Diabetes outcomes and glycemic control
Mean hemoglobin A1c levels  decreased overall  from baseline
(8.7%) to 6-month (8.2%) and 12-month (8.1%) follow-up, al-
though the change was not significant.  After 6 months and 12
months, patients also had a mean increase in average frequency of
hypoglycemia per 2 weeks of blood glucose levels less than 70
mg/dL and less than 40 mg/dL, although these trends were not sig-
nificant.  The mean frequency of hypoglycemia of glucose less
than 70 mg/dL was 3.3 hypoglycemic episodes per 2 weeks at
baseline, 3.3 at 6-month follow-up, and 6.2 at 12-month follow-
up. The average frequency of hypoglycemic episodes per 2 weeks
of glucose less than 40 mg/dL was 0.2 at baseline, 0.2 at 6-month
follow-up, and 0.6 at 12-month follow-up. Clinically, the differ-
ence in severe hypoglycemia (<40 mg/dL) was insignificant, but
hypoglycemia of glucose less than 70 mg/dL increased overall.
The average frequency of hyperglycemia every 2 weeks increased
from  baseline  to  6-month  follow-up  but  was  stable  after  12
months. This trend was observed in hyperglycemic episodes of
glucose greater than 250 mg/dL and greater than 300 mg/dL but
was not significant. The mean frequency of hyperglycemia greater
than 250 mg/dL was 16.3 at baseline, 22.5 at 6-month follow-up,
and 16.2  at  12-month  follow-up.  For  hyperglycemic  episodes
greater than 300 mg/dL, the mean frequency was 4.0 at baseline,
5.4 at 6-month follow-up, and 3.8 at 12-month follow-up.
Lastly, there was a nonsignificant trend toward a decrease in mean
2-week blood glucose levels at 6-month and 12-month follow-up.
Mean daily blood glucose level was 79.2 mg/dL (SD, 20.4 mg/dL;
n = 27) at baseline, 76.2 mg/dL (SD, 15.7 mg/dL; n = 16) at 6
months, and 76.4 mg/dL (SD, 19.7 mg/dL; n = 9) at 12 months.
Time and cost savings
Patients saved a median of 78 minutes of one-way traveling time,
and the VHA saved a median of $72.94 per patient visit in travel
reimbursement. If Atlanta VAMC Endocrinology Telehealth pa-
tients received follow-up appointments every 3 months as recom-
mended, each patient would save 624 minutes of traveling time
per year, which corresponds with VHA savings of $9,336.32 per
year in reimbursements to the 32 patients with type 1 diabetes.
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Telehealth appointment adherence and patient
satisfaction with telemedicine
Telehealth patients had a median of 5 scheduled appointments
(range, 1–10 scheduled appointments). Patients were adherent to
their telehealth appointments; at least half of the patients attended
100% of their appointments, and mean adherence rate was 87.8%
(SD, 17.8%; range, 50.0%–100%).
Twenty-two (69%) telehealth patients with type 1 diabetes com-
pleted the survey about their satisfaction with telehealth care. Pa-
tients perceived the endocrinology care they received during their
telemedicine appointments favorably; 100% of respondents agreed
or strongly agreed that they were satisfied with telehealth (Table
3). Furthermore, 90.9% respondents strongly agreed with the state-
ment that they would recommend telehealth to other veterans, and
90.9% respondents  agreed or  strongly agreed that  they would
rather use telehealth than travel long distances to see their pro-
viders. Two patients who preferred in-person care over telehealth
stated that seeing their physician face-to-face was important to
them.
Discussion
Our findings suggest that telemedicine is a safe method of deliver-
ing type 1 diabetes care to rural patients. Telehealth patients in our
study experienced improvements overall in diabetes outcomes, al-
though our findings were not significant. Patients also had an in-
creased mean frequency of hypoglycemia. Our observation of in-
creased hypoglycemic episodes is consistent with literature that
suggests improved glycemic control, indicated by lower hemo-
globin A1c levels, is correlated with an increased frequency of hy-
poglycemia (13).
Our findings are in line with those of other studies that suggest
that diabetes care via telemedicine is comparable to in-person dia-
betes care. For example, in a recent randomized controlled trial of
282 diabetes patients, those who received telemedicine consulta-
tion had a −1.01% decrease in hemoglobin A1c compared with a
−0.68% decrease in hemoglobin A1c in those receiving in-person
consultation, although the change was nonsignificant (14). Our
findings, which demonstrated a 0.6% decrease in hemoglobin A1c
at 12 months of telemedicine follow-up consultation, complement
this  study’s  findings  and  growing evidence  that  suggests  that
telemedicine is a viable alternative for in-person care.
Previous studies also demonstrated telemedicine’s effectiveness in
delivering diabetes care to rural patients. Wood et al described
telemedicine’s use in pediatric type 1 diabetes care for patients in
rural Wyoming, demonstrated equivalency between telemedicine
and in-person visits, and found that patients received more follow-
up  visits  after  telemedicine’s  implementation  (15).  Similarly,
Wagnild et al described the use of telecommunications for dia-
betes patients  in Montana and found that  patients  showed im-
provements in hemoglobin A1c levels, blood pressure, and dia-
betes knowledge (16). Our findings are consistent with literature
that suggests that telemedicine may effectively deliver diabetes
care to rural patients.
Our study has limitations. First, the referring diabetes specialty
provider at CAVHCS also independently manages the diabetes
treatment of many of the patients enrolled in the telehealth clinic,
in some cases just before referral to the telehealth clinic but mostly
with select patients between telehealth visits as needed. Thus, tele-
health patients’ glycemic control before baseline visits and after-
ward may have been better than that of patients who receive care
only from primary care providers (17). However, use of midlevel
providers such as pharmacists and nurses is common across the
VA health system, is an integral part of the VA-established Pa-
tient Aligned Care Team model, and may represent the patient-
centered care model in use (18).
Another limitation was significant loss of follow-up. Many pa-
tients had follow-up visits that did not meet our study criteria of 6-
and 12-month follow-up points. This apparent loss of follow-up
may have been because the Atlanta VA Telehealth Endocrinology
Clinic is available only once per week. As more patients enrolled
in the clinic over time, the intervals between follow-up appoint-
ments necessarily increased. Therefore, some patients did not have
an appointment scheduled at the 6-month point (5–7 months after
baseline) or the 12-month point (11–13 months after baseline).
Thus, if a patient had an appointment before 11 months or over 13
months after their initial appointment, they would not have been
included for the 12-month follow-up analysis. Our follow-up data
may have been further confounded by the possibility that patients
with worse glycemic control needed more frequent follow-up and
thus were more likely to have 12-month follow-up data.
Additionally, our study used convenience sampling of patients en-
rolled in the Atlanta VAMC Endocrinology Telehealth Clinic. Our
findings may not accurately represent patients with type 1 dia-
betes in the general population because all our patients were veter-
ans seen at the VA and most had insulin pumps, which are associ-
ated with better glycemic control compared with insulin injections
(19). Furthermore, our evaluation of aspirin use may have been
limited by inconsistent documentation of its use, because many
patients purchase it over-the-counter at local drug stores, leading
to an underestimation of its use.
Lastly, our limitations include self-selection bias and small sample
size. Self-selection bias may have affected our satisfaction survey
results because patients who prefer telemedicine may be more
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likely to enroll in telehealth clinics, whereas patients who prefer
in-person care may be more likely travel to VA medical centers to
receive treatment. Furthermore, our small sample size limited our
statistical power and generalizability. However, these limitations
were inherent in our study design, because we conducted a retro-
spective review of only patients enrolled in our telehealth clinic.
One of telemedicine’s most important benefits is its ability to in-
crease access to health care. Distance is a significant factor for
many veterans living in remote and rural areas seeking health care,
because travel distance is negatively correlated with use of outpa-
tient services (20). The VA has mitigated this issue by providing
travel reimbursement and bus services for patients, but telemedi-
cine further promotes health care accessibility for rural patients.
Another important aspect of telemedicine is its acceptance by pa-
tients and providers. Our study demonstrates that most patients are
satisfied with telemedicine care, believe that telemedicine appoint-
ments are convenient, and would recommend telemedicine to oth-
er veterans. Our findings are consistent with those of studies that
report that both patients and providers are highly satisfied with
telemedicine (21–24).
Lastly, our findings suggest that telemedicine leads to substantial
cost savings and complement findings from studies that demon-
strate telemedicine’s cost-saving capacity in larger health care sys-
tems.  For example,  the use of  telemedicine in 7 rural  hospital
emergency departments in Mississippi decreased the hospitals’ ex-
penditures from $7.6 million to $1.1 million during a 5-year peri-
od with no apparent effect on clinical outcomes (25). If the VHA
implements telemedicine on a broader scale, veterans could re-
ceive more accessible patient-centered care, and the VHA could
benefit from significant cost savings.
Our findings suggest that telemedicine delivers safe diabetes care
to rural veterans and supports growing evidence that suggests that
telemedicine is an effective alternative method of health care de-
livery. Additionally, telemedicine is associated with cost savings
for the VHA, time savings for patients, high appointment adher-
ence,  and high patient  satisfaction.  Future studies  with larger,
more representative samples of patients with type 1 diabetes are
needed  to  elucidate  telemedicine’s  effectiveness  in  providing
health care to broader patient populations.
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Tables
Table 1. Demographic Characteristics of Patients, Study of Patients (N = 32) Enrolled in the Atlanta VA Telehealth Endocrine Clinic, June 2014 to October 2016
Characteristic Telehealth Patients With Type 1 Diabetes at Baseline (N = 32)a
Mean (SD) age, y 53.5
Sex
Male 90.6
Female 9.4
Race
White 84.4
Black 15.6
Primary care location
Montgomery, Alabama 75.0
Columbus, Georgia 25.0
Carrollton, Georgia 0
Mean (SD) body mass index, kg/m2 27.6
Mean (SD) duration of diabetes, y 24.7
Insulin pump use 75.0
Continuous glucose monitor use 18.8
Hypertension 46.9
Hyperlipidemia 81.3
Hypothyroidism 28.1
Tobacco use 21.9
Microvascular diseases
Neuropathy 71.9
Nephropathy 21.0
Retinopathy 40.6
Macrovascular diseases
Coronary Artery disease 25.0
Cerebrovascular disease 12.5
Peripheral vascular disease 3.1
a Values are percentages unless otherwise indicated.
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Table 2. Maintenance of Standard Processes of Diabetes Care, Study of Patients (N = 32) Enrolled in the Atlanta VA Telehealth Endocrine Clinic, June 2014 to Octo-
ber 2016
American Diabetes Association 2016
Guideline Monitoring
Percentagea of
Patients With
Recommended Care at
Baseline
Percentagea of
Patients With
Recommended Care at
6 Months
Percentagea of
Patients With
Recommended Care at
12 Months
Blood pressure Every routine visit 100 (32 of 32) 100 (17 of 17) 100 (9 of 9)
Diabetic retinopathy eye exam Every 1 year 93.7 (30 of 32) 94.1 (16 of 17) 100 (9 of 9)
Urine microalbumin-to-creatinine ratio Every 1 year 81.3 (26 of 32) 88.2 (15 of 17) 88.9 (8 of 9)
Lipid panel (triglyceride, HDL, and LDL levels) Every 1 year 100 (32 of 32) 100 (17 of 17) 100 (9 of 9)
Statin use Eligibility: aged >40 y or history of CVD 88.9 (24 of 27) 100 (15 of 15) 87.5 (7 of 8)
Aspirin use Eligibility: aged >50 or history of CVD 63.6 (14 of 22) 69.2 (9 of 13) 50.0 (1 of 2)
Abbreviations: CVD, cardiovascular disease; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol.
a Values in parentheses are number of patients who adhered to recommendation out of total number.
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Table 3. Patient Responses to Telehealth Satisfactiona Survey, Study of Patients With Type 1 Diabetes (N = 32) Enrolled in the Atlanta VA Telehealth Endocrine Clin-
ic, June 2014 to October 2016
Telehealth Patient Satisfaction Survey Question Median Mean (SD)
I felt comfortable with the equipment used. 5.00 4.91 (0.29)
I was able to see the clinician clearly. 5.00 4.95 (0.21)
I was able to hear the clinician clearly. 5.00 5.00 (0)
There was enough technical assistance for my meeting with the clinician. 5.00 4.95 (0.21)
My relationship with the clinician was the same during this session as it is in person. 5.00 4.18 (1.01)
The location of the telehealth clinic is convenient for me. 5.00 4.68 (0.65)
My needs were met during the session. 5.00 4.95 (0.21)
I received good care during the session. 5.00 4.95 (0.21)
The telehealth clinic provided the care I expected. 5.00 4.95 (0.21)
Overall, I am satisfied with the telehealth session. 5.00 4.91 (0.29)
I would recommend this type of session to other veterans. 5.00 4.77 (0.75)
I would rather use telehealth to receive this service than travel long distance to see my provider. 5.00 4.59 (1.05)
a Patient satisfaction was measured using a Likert Scale (from 1 through 5), where 1 indicated “strongly agree” and 5 indicated “strongly disagree.”
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